Table 9.

Cox regression analysis for rivaroxaban and apixaban in the PS-trimmed and PS-matched cohorts and post hoc PS extended sensitivity analysis

Hazard ratios (95% CI)	PS-matched cohort*	PS-trimmed cohort	Post hoc PS stratification with extended PS
	Rivaroxaban (n = 3563) Apixaban (n = 3563)	Rivaroxaban (n = 3792) Apixaban (n = 4223)	Rivaroxaban (n = 3787) Apixaban (n = 4192)
Composite outcome	1.01 (0.82–1.25)	1.04 (0.86–1.26)	1.05 (0.87–1.28)
Stroke	0.78 (0.52–1.19)	0.83 (0.57–1.21)	0.84 (0.58–1.22)
Major bleeding	1.54 (1.14–2.08)	1.61 (1.22–2.12)	1.73 (1.30–2.28)
Myocardial infarction	0.96 (0.63–1.45)	0.97 (0.67–1.39)	0.98 (0.68–1.41)
All-cause death	0.97 (0.80–1.19)	1.06 (0.89–1.28)	1.07 (0.89–1.29)

PS propensity score; CI confidence interval

Variables that were selected for the primary analysis and the PS adjustment analysis can be found in the Supplemental material

^*Unbalanced covariates: previous oral anticoagulant use within 3 months